The reduction in CV and renal risk appears to be independent of the level of hyperglycaemia in patients (Perkovic et al., 2019), and following meta‐analysis of clinical trial data, the United States Food and Drug Administration (FDA) have recently approved the use of SGLT2 inhibitors in non‐diabetic patients with heart failure and reduced ejection fraction (Zannad et al., 2020). This evidence concerns the gene SLC5A2 and Hyperglycemia.